Evidence map›Paper›PMID 29088806›Full record

ArticleOncotarget2017

High amplification of FGFR1 gene is a delayed poor prognostic factor in early stage ESCC patients.

Qi Song, Yalan Liu, Dongxian Jiang, Haixing Wang, Jie Huang, Yifan Xu, Akesu Sujie, Haiying Zeng, Chen Xu, Yingyong Hou

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Alterations inContemporary oncology (Poznan, Poland) · 2025
    Article
  3. Article
  4. Aberrant Expression of FGFRL1 in Esophageal Cancer and Its Regulation by miR-107.Asian Pacific journal of cancer prevention : APJCP · 2023
    Article
  5. Review
  6. Article
  7. Prognostic and clinicopathological significance ofAnnals of translational medicine · 2019
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Qi SongDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Yalan LiuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Dongxian JiangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Haixing WangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Jie HuangDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Yifan XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Akesu SujieDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Haiying ZengDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Chen XuDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Yingyong HouDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, P. R. China.
Fudan University · CNZhongshan Hospital · CNThe First Affiliated Hospital, Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplification of the fibroblast growth factor receptor 1 (

Indexed as

clinical stagedisease free survival timeESCCFGFR1 high amplificationprognostic marker

Identifiers

PMID29088806
PMCPMC5650361
OpenAlexW2745173311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.